S. Ou

J. Shiraishi, M. Ando, S. Ou, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study

A. Shaw, S. Ou, T. Mok, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II evaluation of eribulin mesylate (E7389, NSC 707389) in patients with metastatic or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group trial S0618

M. Leblanc, S. Ou, J. Moon, 2011, Investigational New Drugs.

Preliminary Clinical Activity of Repotrectinib (TPX‐0005) in Advanced ROS1 Fusion‐Positive Non‐Small Cell Lung Cancer: OA09

A. Drilon, A. Shaw, S. Ou, 2018, Journal of Thoracic Oncology.

Epidemiology of nasopharyngeal carcinoma in the United States: improved survival of Chinese patients within the keratinizing squamous cell carcinoma histology.

J. Zell, A. Ziogas, H. Anton-Culver, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Crizotinib in patients (pts) with MET-amplified non-small cell lung cancer (NSCLC): Updated safety and efficacy findings from a phase 1 trial.

Jeffrey W. Clark, S. Ou, S. Ou, 2018 .

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

Jeffrey W. Clark, A. Iafrate, P. Jänne, 2010, The New England journal of medicine.

Mechanisms of Resistance to Selective RET Tyrosine Kinase Inhibitors in RET Fusion-Positive Non-Small Cell Lung Cancer.

M. Mino‐Kenudson, L. Sequist, S. Ou, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

TEMPORARY REMOVAL: Updated overall survival and final progression-free survival data for patients with treatment-naïve advanced ALK-positive non-small-cell lung cancer in the ALEX study.

A. Shaw, S. Ou, T. Mok, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC).

Jeffrey W. Clark, A. Iafrate, A. Shaw, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies ( NP 28673 1 and NP 28761 ) of Alectinib in ALK-positive Non-Small-Cell Lung Cancer

Jie Yang, R. Govindan, A. Shaw, 2017 .

Alectinib versus crizotinib in treatment-naive advanced ALK-positive non-small cell lung cancer (NSCLC): Primary results of the global phase III ALEX study.

Rafal Dziadziuszko, Johannes Noe, Rafael Rosell, 2017 .

ERBB family fusions are recurrent and actionable oncogenic targets across cancer types

S. Ou, R. Doebele, R. Kurzrock, 2023, Frontiers in Oncology.

MA04.03 Immunotherapy for Non-Small Cell Lung Cancers (NSCLC) with Oncogenic Driver Mutations: New Results from the Global IMMUNOTARGET Registry

A. Drilon, H. Wakelee, S. Ou, 2018, Journal of Thoracic Oncology.

Innovative personalized medicine in gastric cancer: time to move forward

S. Ou, S. Ou, W. Kang, 2014, Clinical genetics.

Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology.

A. Iafrate, M. Mino‐Kenudson, S. Ou, 2012, The oncologist.

1334TiPRANDOMISED, MULTICENTRE, PHASE III, OPEN-LABEL STUDY OF ALECTINIB VS CRIZOTINIB IN TREATMENT-NAïVE ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE ADVANCED NSCLC (ALEX STUDY).

T. Mok, S. Ou, S. Peters, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Updated results from TIGER-X, a phase I/II open label study of rociletinib in patients (pts) with advanced, recurrent T790M-positive non-small cell lung cancer (NSCLC).

H. Wakelee, L. Sequist, S. Ou, 2016 .

The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma.

S. Ou, S. Ou, J. Kim, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Innovative personalized medicine in gastric cancer: time to move forward

S. Ou, Kwanmien Kim, W. Kang, 2014, Clinical genetics.